PD-L1/TIGIT bispecific antibody showed survival advantage in animal model

Songlin Mu; Zhijuan Liang; Yongmei Wang; Wendi Chu; Yi-Li Chen; Qi Wang; Guifeng Wang; Chunhe Wang

doi:10.1002/ctm2.754

PD-L1/TIGIT bispecific antibody showed survival advantage in animal model

Clin Transl Med. 2022 May;12(5):e754. doi: 10.1002/ctm2.754.

Authors

Songlin Mu^{1

2}, Zhijuan Liang^{1

2}, Yongmei Wang^{1

2}, Wendi Chu^{1

2}, Yi-Li Chen^{3

4}, Qi Wang^{1

2}, Guifeng Wang^{1

2}, Chunhe Wang^{1

2

3}

Affiliations

¹ Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
² University of Chinese Academy of Sciences, Beijing, China.
³ Dartsbio Pharmaceuticals, Ltd., Zhongshan, China.
⁴ Shanghai Mabstone Biotechnologies, Ltd., Shanghai, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Bispecific* / therapeutic use
B7-H1 Antigen*
Disease Models, Animal
Receptors, Immunologic

Substances

Antibodies, Bispecific
B7-H1 Antigen
Receptors, Immunologic

Associated data

ClinicalTrials.gov/NCT05102214